2 In vivo, indomethacin enhances the pressor action of angiotensin II (All) in healthy man, 3 ' 4 and an enhanced pressor response to All and NE has been described in some indomethacin-treated patients with Bartter's syndrome.
T HE inhibition of prostaglandin synthesis with indomethacin 1 has been shown to interfere with the vascular sensitivity to various vasoconstrictor stimuli in vitro. 2 In vivo, indomethacin enhances the pressor action of angiotensin II (All) in healthy man, 3 ' 4 and an enhanced pressor response to All and NE has been described in some indomethacin-treated patients with Bartter's syndrome. 68 Studies of the influence of prostaglandin inhibition by indomethacin on the release of endogenous catecholamines in man have indicated an inhibitory effect on the release of NE, 9 although other authors 10 have failed to confirm this observation.
To examine the influence of prostaglandin inhibition upon the vasoactive effects of both exogenous and endogenous catecholamines, we studied the pressor action of exogenous NE as well as the changes in blood pressure, pulse rate, and plasma catecholamines during orthostasis and cold pressor test in healthy subjects prior to and following the administration of indomethacin.
Experimental Protocol

Subjects
Six healthy male volunteers aged 20 to 26 years (mean, 23 ± 1 years) whose weight was 90% to 110% of ideal body weight (based on Metropolitan Life insurance tables, 1959) were included in the study. The purpose and potential risks of the study were carefully explained to all subjects, and written, informed consent was obtained before their participation. No medication was permitted for at least 6 weeks before the study. All subjects fasted overnight and abstained from alcoholic beverages, coffee, and cigarette smoking for at least 12 hours prior to each test. They ate their regular diet on an outpatient basis, with 6 g of supplementary salt (2 g t.i.d.) for 3 days. On the third day, a 24-hour urine collection was made to determine urinary sodium (Na + ) and potassium (K + ) concentrations. The subjects were in the supine position for 2 hours before each test, and 60 minutes before the beginning of the experimental protocol they had indwell-ing catheters inserted in each antecubital vein, one for infusion and the other for blood sampling. The sequence of the subsequent functional studies was: orthostasis, cold pressor test, i.v. NE.
Functional Studies
Orthostasis
Blood pressure (BP) and pulse rate (PR) measurements were taken supine at 5-minute intervals for an initial observation period of 30 minutes. Then the subjects assumed an upright position for 10 minutes, for BP and PR determinations at 2-minute intervals; they then reassumed the supine position for BP and PR control every 5 minutes for 30 minutes. Blood samples were drawn at -15,0, 2, 8, and 10 minutes to determine E and NE. In addition, blood samples were obtained at -15 and 0 minutes for the determination of plasma aldosterone and the serum concentrations of Na + and K + .
Cold Pressor Test
Following an observation period of 15 minutes during which BP and PR were measured at 5-minute intervals, the subjects were asked to immerse their hands and forearms in ice water for 2 minutes. BP and PR were measured at 1 and 2 minutes during immersion as well as 3, 4, 5, 10, and 15 minutes after the start of immersion. Blood samples for the determination of E and NE were drawn at -1 5 , 0, 1, and 2 minutes.
Administration of Norepinephrine
Following an initial observation period of 15 minutes with BP and PR measurements at 5-minute intervals, NE (Arterenol, Hoechst A C , Frankfurt/ Main, Federal Republic of Germany, diluted in 0.9% saline) was administered by constant (1 ml/min) infusion at fixed rates of 50, 100, and 200 ng kg 1 min 1 ; t = 15 minutes each). BP and PR measurements were continued at 5-minute intervals. Blood samples for the determination of E and NE were obtained at -1 5 , 0, and at 14, 29, and 44 minutes (i.e.: 1 minute before the end of the infusion of each single dose of NE).
Equilibration periods of 60 minutes were observed between the various functional studies. The tests were repeated under otherwise identical conditions after oral ingestion of 3 X 50 mg indomethacin (Indocin, Merck, Sharp and Dohme, Haarlem)/day for 3 days. The last dose of indomethacin was given 2 hours before starting the procedures according to the experimental protocol. The sequence of the indomethacin and control studies, which were 1 week apart, was randomized.
Methods
All BP readings were taken by the same person using a cuff sphygmomanometer. Mean blood pressure (BP m ) was calculated as diastolic BP plus one-third of pulse height.
Concentrations of Na
+ and K + in urine and serum were determined by flame photometry. Aldosterone was determined radioimmunologically following extraction by dichloromethane and thin layer chromatography (cyclohexane -ethyl acetate 20:80)." Plasma concentrations of NE and E were determined by radioenzymatic analysis based on the conversion of the catecholamines into their o-methylated analogs by catechol-o-methyltransferase in the presence of Sadenosyl-methionine- 3 H. 12 The intra-and interassay coefficients of variation for plasma aldosterone, E, and NE were < 10%.
Data in text and figures are presented as x ± SE. Student's t test for matched pairs and analysis of variance were used for statistical evaluation.
Results
Following administration of indomethacin in the sodium-repleted state, no change was observed in body weight (75.8 ± 5.5 kg in the untreated vs 76.3 ± 5.3 kg in the indomethacin-treated subjects), in urinary volume (basal: 1470 ± 98 ml untreated vs 1387 ± 142 ml treated), in Na + -excretion (249.0 ± 18.3 mmole/day untreated vs 219.5 ± 16.7 mmole/ day treated), in K + -excretion (131.3 ± 15.0 mmole/ day untreated vs 119.7 ± 10.2 mmole/day treated), as well as in serum sodium (142.3 ± 0.8 mmole/liter untreated vs 142.5 ± 1.2 mmole/liter treated) and potassium (4.4 ± 0.07 mmole/liter untreated vs 4.6 ± 0.2 mmole/liter treated. Following administration of indomethacin, plasma aldosterone was suppressed (without indomethacin, 5.3 ± 0.6 ng/100 ml; after indomethacin, 3.7 ± 0.8 ng/100 ml; p < 0.05).
Changes in Blood Pressure and Pulse Rate During Orthostasis and Cold Pressor Test
Orthostasis induced an initial rise in diastolic BP from 77.3 ± 3.0 to 84.2 ± 2.7 mm Hg (p < 0.01) without indomethacin and from 80.7 ± 2.2 mm Hg to 85.0 ± 4.3 mm Hg (n.s.) after the application of indomethacin. This was followed by a fall in diastolic BP to 75.8 ± 6.2 mm Hg without indomethacin (n.s.) and to 70.8 ± 7.2 mm Hg following indomethacin (n.s.). Systolic BP fell from 118.2 ± 1.2 mm Hg to 108.3 ± 4.2 mm Hg (before indomethacin; p < 0.05) and from 117.5 ± 3.8 mm Hg to 106.7 ± 8.2 mm Hg (after indomethacin; n.s.). Thus, BP m fell from 91.0 ± 2.4 mm Hg to 86.7 ± 6.2 mm Hg (n.s.) and from 93.3 ± 1.9 mm Hg to 88.3 ± 4.2 mm Hg (n.s.) respectively ( fig. 1 ).
In subjects without medication, cold pressor test induced a rise in diastolic BP (80. Basal blood pressure (diastolic, systolic, and mean) as well as the observed maximal and overall changes (as judged by analysis of variance) in diastolic BP, systolic BP, and BP m both during orthostasis and during cold pressor test were not influenced by pretreatment with indomethacin.
A significant (p < 0.05 to < 0.005)-increase in PR was seen both during orthostasis and cold pressor test prior to as well as following administration of indomethacin. Basal PR was lower following treatment with indomethacin than without indomethacin both prior to orthostasis (63 ± 5 vs 67 ± 5 beats/min;/? < 0.005) and prior to cold pressor test (64 ± 5 vs 69 ± 6 beats/min; p < 0.05). Although the overall response of PR both during orthostasis and cold pressor test was not influenced by treatment with indomethacin (analysis of variance, p > 0.05), a lower PR was observed intermittently both during orthostasis and cold pressor test (p < 0.05).
Plasma Catecholamines During Orthostasis and During Cold Pressor Test
Plasma concentrations of NE during orthostasis and cold pressor test are shown in table 1. Administration of indomethacin did not influence basal NE prior to orthostasis and prior to cold pressor test. An increase in plasma NE concentrations above basal levels during orthostasis was observed both before {p < 0.01) and after indomethacin administration (p < 0.0005). A rise in plasma NE was also to be seen during cold pressor test both without indomethacin (p < 0.05) and following indomethacin (p < 0.05) treatment. Maximum concentrations of plasma NE were higher during orthostasis than during cold pressor test without indomethacin as well as after indomethacin administration (p < 0.01 and < 0.05 respectively). Indomethacin did not induce any differences in the individual maximal concentrations of NE during orthostasis (377.5 ± 19.8 pg/ml vs 502.3 ± 47.4 pg/ml without indomethacin, n.s.) or during cold pressor test (293.8 ± 33.4 pg/ml vs 300.7 ± 51.1 pg/ml without indomethacin, n.s.). However, analysis of variance revealed a smaller overall response of plasma NE to orthostasis after indomethacin when compared to the untreated state (p < 0.05). The overall response of NE to cold pressor test did not appear to be influenced by indomethacin, as calculated by analysis of variance (p > 0.05).
Plasma concentrations of E during orthostasis and cold pressor test are shown in table 2. Treatment with indomethacin did not influence basal E prior to orthostasis or to cold pressor test. Neither orthostasis nor cold pressor test induced a significant rise in plasma E above basal concentrations. Maximal plasma E concentrations during orthostasis were not different from those seen during cold pressor test both in the untreated state and following treatment with indomethacin. , FIGURE 
Mean blood pressure (BP^ mm Hg) and pulse rate (PR X min~l) in healthy, male subjects (n = 6) during orthostasis and cold pressor test (CPT) prior to (o o) and after (• ») treatment with indomethacin (x ± SE).
Indomethacin also failed to induce any differences in the individual maximal concentrations of E during orthostasis (106.7 ± 16.8 pg/ml following indomethacin vs 133.3 ± 26.4 pg/ml in the untreated state; n.s.) or during cold pressor test (105.7 ±13.1 pg/ml vs 111.7 ± 9.6 pg/ml in the untreated state; n.s.). No difference was found in the overall response of E to orthostasis or cold pressor test between the indomethacin-treated and the untreated state (p > 0.05).
Effect of Exogenous Noreplnephrine
The pressor response observed in the six subjects during the i.v. administration of 50, 100, and 200 ng NE kg^min" 1 ( fig. 2 ) was unaltered by pretreatment with indomethacin as calculated by analysis of variance. Pulse rate during the infusion of norepinephrine was similar in the untreated state and after indomethacin administration. Plasma concentrations of NE were identical (table 3) at the end of the respective infusion periods of NE for the untreated and the indomethacin-treated state. Plasma concentrations of E did not change while NE was infused. 
TABLE 3 Plasma Concentrations of Norepinephrine (pg/ml) m Six Normal Men (x ± SE) Following the Intravenous Administration of Various Doses of Norepinephrine Prior to and After Treatment with Indomethacin
Discussion
The functional capacity of the sympathetic nervous system has been tested in humans by various stimuli including orthostasis and the cold pressor test. Both maneuvers result in an increase of plasma catecholamine (predominantly NE) concentrations.
1 *" 18 The expected changes in BP and pulse rate during orthostasis and cold pressor test were observed in the six healthy subjects in this study. Orthostasis proved to be a more powerful stimulus for NE secretion than the cold pressor test, while changes in plasma E during both maneuvers were not significant. Little information is available about the impact of endogenous prostaglandins on both the release and the vasoactive effects of catecholamines in vivo. The six subjects presented in this study were given a dose of indomethacin that has been shown to decrease urinary PG excretion by 71%." Thus, although concentrations of prostaglandins were not determined in this study, inhibition of endogenous prostaglandin synthesis can be assumed. This may also explain the observed suppression in plasma aldosterone following indomethacin when compared to the untreated yet sodium-repleted state, as decreased concentrations of aldosterone have previously been observed in healthy subjects following treatment with indomethacin. 4 Treatment with indomethacin neither modified basal BP nor the changes in BP during orthostasis and cold pressor test. The observed decrease in pulse rate following treatment with indomethacin is in accordance with observations by others 17 and could be due to the constant, albeit not significant, elevation of BP during treatment with indomethacin. Whereas basal plasma concentrations of E and NE as well as the concentrations of E during orthostasis and cold pressor test were uninfluenced by pretreatment with indomethacin, plasma concentrations of NE during orthostasis were lower in the indomethacin-treated state when compared to the untreated state by analysis of variance. It is conceivable that indomethacin was not equally effective in inhibiting prostaglandin synthesis in the adrenal medulla and in sympathetic neuronal junctions, thus accounting for the different behavior of E and NE. Possibly due to the large range in the observed concentrations of NE no significant differences were found between the individual maximal concentrations of NE during orthostasis in the untreated vs the indomethacin-treated state. Since sympathetic nervous activity in normal subjects decreases with sodium loading, 18 the high sodium-uptake in the subjects presented in this study may have blunted the release of NE during orthostasis. This may account for the less clearcut suppression of NE release by indomethacin in comparison to data recently published by GQllner et al., 9 who found decreased concentrations of NE (basal and after orthostasis) following treatment with indomethacin in normal subjects consuming 59 mmoles Na + /day. Emotional factors affecting catecholamine release 1 ' are not likely to account for the discrepancies between our data and those of Gflllner et al., since both studies were performed in a randomized setup. A recent report on unaltered plasma catecholamines in indomethacin-treated normal men prior to and following orthostasis 10 is difficult to evaluate in this context, since no data on sodium uptake are given.
Following pretreatment with indomethacin, the pressor response upon the infusion of various doses of NE was unchanged in the six subjects presented in this study. These data fail to confirm an enhanced pressor response in indomethacin-treated healthy men as described in abstract form by Guthrie et al.
w However, that study may not have been performed in a randomized set up.
Our data are not necessarily in conflict with results obtained in vitro which indicate a modulatory influence of prostaglandins upon the vasoactive actions of NE, 8 since these interactions vary considerably between different prostaglandins 31 and different vascular beds. Thus, the pressor action of NE is potentiated by PGEj in some in vitro systems, while it is attenuated in others." Moreover, the inhibition of endogenous prostaglandins has failed to modify vasoconstrictor responses in some in vitro experiments." Our results suggest that in man there is no overall effect of prostaglandin inhibition upon the pressor action of exogenous NE under physiological conditions. This effect may be of more importance when prostaglandin synthesis is stimulated under basal conditions, thus explaining the increased pressor response to NE in some indomethacin-treated patients with Bartter's syndrome. 6 ''
The enhanced pressor action of All observed in indomethacin-treated healthy subjects*' * may be due in part to decreased concentrations of endogenous All, resulting from a direct and/or indirect suppression of renin. Decreased concentrations of endogenous All render the vascular All receptors more sensitive to the actions of exogenous A l l . " From our results it appears that the enhanced pressor response of All in indomethacin-treated healthy subjects is a phenomenon that doesn't necessarily apply to other vasoconstrictor agents.
In conclusion, our data suggest that a suppression of NE release occurs following treatment with indomethacin in healthy subjects. However it appears that the inhibition of prostaglandin synthesis by indomethacin does not have any impact on the release of E or on the pressor response to exogenous NE in healthy man. Although these results do not exclude interactions of endogenous prostaglandins and catecholamines in local circulatory control, they indicate that the inhibition of prostaglandin synthesis does not have a major impact on the vasoactive actions of catecholamines in normal man. 
